Maze Therapeutics, Inc. (NASDAQ:MAZE) Stock Now Rated "Buy" by Sell-Side Analysts

Maze Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts maintain a Buy consensus on Maze Therapeutics: nine of 13 analysts rate it Buy, three Strong Buy and one Sell. The average 12-month price target is $65.50.
  • Maze reported a quarterly loss of $0.79 per share, slightly worse than the $0.78 loss analysts expected; analysts forecast a full-year loss of $2.75 per share.
  • Company insiders sold 176,849 shares worth about $4.74 million over the past 90 days. The reported sales were made under pre-arranged trading plans.
  • Five stocks we like better than Maze Therapeutics.

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) have been given a consensus recommendation of "Buy" by the thirteen analysts that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, nine have given a buy recommendation and three have assigned a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $65.50.

Several analysts have issued reports on MAZE shares. Weiss Ratings reissued a "sell (d-)" rating on shares of Maze Therapeutics in a research note on Monday, September 21st. Wall Street Zen downgraded shares of Maze Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. Canaccord Genuity Group started coverage on Maze Therapeutics in a research note on Monday, October 19th. They set a "buy" rating and a $75.00 target price on the stock. BTIG Research reiterated a "buy" rating and issued a $46.00 price target on shares of Maze Therapeutics in a research report on Tuesday, September 22nd. Finally, JPMorgan Chase & Co. decreased their price target on Maze Therapeutics from $53.00 to $51.00 and set an "overweight" rating on the stock in a research report on Wednesday, November 11th.

View Our Latest Research Report on MAZE

Insider Activity

In other Maze Therapeutics news, CMO Harold Bernstein sold 16,141 shares of the stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $26.36, for a total transaction of $425,476.76. Following the transaction, the chief marketing officer directly owned 16,141 shares in the company, valued at approximately $425,476.76. This represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of Maze Therapeutics stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $27.58, for a total value of $206,850.00. Following the transaction, the insider directly owned 26,250 shares in the company, valued at approximately $723,975. The trade was a 22.22% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 176,849 shares of company stock valued at $4,741,878 in the last ninety days. 5.30% of the stock is owned by company insiders.

Institutional Trading of Maze Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Sterling Capital Management LLC grew its stake in shares of Maze Therapeutics by 390.5% during the 3rd quarter. Sterling Capital Management LLC now owns 1,089 shares of the company's stock valued at $30,000 after acquiring an additional 867 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Maze Therapeutics during the second quarter valued at approximately $48,000. Royal Bank of Canada grew its holdings in Maze Therapeutics by 214.1% during the 1st quarter. Royal Bank of Canada now owns 2,029 shares of the company's stock valued at $61,000 after purchasing an additional 1,383 shares during the last quarter. Quantbot Technologies LP purchased a new stake in shares of Maze Therapeutics in the second quarter valued at approximately $80,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in Maze Therapeutics in the third quarter valued at about $77,000.

Maze Therapeutics Price Performance

NASDAQ MAZE opened at $32.43 on Friday. The company has a current ratio of 14.14, a quick ratio of 14.14 and a debt-to-equity ratio of 0.09. The company has a fifty day simple moving average of $29.25 and a 200 day simple moving average of $31.30. Maze Therapeutics has a 1 year low of $21.95 and a 1 year high of $53.65. The company has a market cap of $1.77 billion, a P/E ratio of -12.24 and a beta of 2.04.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last posted its earnings results on Monday, November 9th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.78) by ($0.01). On average, sell-side analysts predict that Maze Therapeutics will post -2.75 EPS for the current year.

About Maze Therapeutics

(Get Free Report)

Maze Therapeutics is a clinical-stage biotechnology company developing precision medicines for people with serious diseases. Its research uses human genetics and functional genomics to identify disease-related biological pathways and potential drug targets. The company's Maze Compass platform is designed to connect genetic insights with biological research to guide drug discovery and development. Its investigational programs have included approaches for APOL1-mediated kidney disease and Pompe disease; these are not marketed treatments.

Read More

Analyst Recommendations for Maze Therapeutics (NASDAQ:MAZE)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Maze Therapeutics Right Now?

Before you consider Maze Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.

While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines